Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMOXAPINE vs AMITID
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective inhibitor of serotonin reuptake and, to a lesser extent, norepinephrine reuptake. Also exhibits weak dopamine D2 receptor antagonism and alpha1-adrenergic blockade.
Amitriptyline inhibits the reuptake of serotonin and norepinephrine, increasing their levels in the synaptic cleft. It also blocks histamine H1, alpha-adrenergic, and muscarinic receptors.
Major depressive disorder,Anxiety,Panic disorder,Off-label: neuropathic pain, insomnia
Major depressive disorder,Neuropathic pain,Fibromyalgia,Migraine prophylaxis,Chronic tension-type headache,Irritable bowel syndrome,Enuresis
200-300 mg/day orally in divided doses, initially 50 mg three times daily; maximum 400 mg/day
75–150 mg orally once daily at bedtime; maximum 200 mg daily. For depression, initial dose 25–75 mg/day, titrate up to 150 mg/day. For neuropathic pain, start 10–25 mg at bedtime, increase to 25–100 mg/day.
Parent drug: 8-12 hours; active metabolite (8-hydroxyamoxapine): approximately 30 hours; steady-state achieved in 3-5 days
Terminal elimination half-life is 7-10 hours; clinically, steady-state is reached within 2-3 days.
Primarily hepatic via CYP2D6 and CYP3A4; major metabolite is 8-hydroxyamoxapine, which is pharmacologically active.
Hepatic via CYP2D6, CYP2C19, CYP3A4; active metabolite nortriptyline.
Primarily renal (approximately 60-70% as metabolites, <5% unchanged); minimal fecal elimination (<10%)
Renal: 60-80% as metabolites, <5% unchanged; Biliary/Fecal: 20-30% as metabolites.
Approximately 80-90%, primarily to albumin and alpha-1-acid glycoprotein
90-95% bound primarily to albumin and α1-acid glycoprotein.
0.8-1.2 L/kg, indicating extensive tissue distribution
3-5 L/kg; indicates extensive tissue distribution.
Oral: approximately 60-70% due to first-pass metabolism
Oral: 60-70%; Intravenous: 100%.
GFR 10-50 m L/min: reduce dose by 50%; GFR <10 m L/min: avoid use or reduce dose by 75%
GFR ≥30 m L/min: no adjustment. GFR 15–29 m L/min: reduce dose by 50%. GFR <15 m L/min: contraindicated or use with extreme caution, maximum 25 mg/day.
Child-Pugh Class A: start at 25 mg twice daily; Class B: 25 mg once daily; Class C: avoid use
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use.
Not recommended for use in children under 16 years
Not FDA-approved for use in children <12 years. For adolescent depression (off-label): start 25 mg/day, titrate up to 50–100 mg/day. Weight-based: 1–3 mg/kg/day, not to exceed 150 mg/day.
Initial dose 25 mg twice daily, increase slowly; maximum 300 mg/day
Start at 10–25 mg orally at bedtime; increase by 10–25 mg every 3–7 days to effective dose, typically 50–75 mg/day. Maximum 100 mg/day due to increased risk of anticholinergic effects, sedation, and orthostatic hypotension.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
Antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
Suicidality risk in young adults,Serotonin syndrome when combined with other serotonergic drugs,Extrapyramidal symptoms due to weak D2 blockade,Seizure risk,Cardiotoxicity (prolonged QT interval) at high doses,Agranulocytosis (rare)
Clinical worsening and suicide risk,Serotonin syndrome,Cardiovascular effects (QT prolongation, arrhythmia),Anticholinergic effects,Seizures,Angle-closure glaucoma,Urinary retention,Hepatic impairment,Hyponatremia
Hypersensitivity to amoxapine or any dibenzoxazepine,Concomitant use with MAOIs (including linezolid and methylene blue),Recent myocardial infarction,Uncontrolled narrow-angle glaucoma,Urinary retention,QT prolongation or concurrent use of drugs that prolong QT
Hypersensitivity to amitriptyline,Concomitant use with MAOIs (within 14 days),Acute recovery phase after myocardial infarction,Concurrent use of cisapride or other QT-prolonging drugs
Avoid alcohol and beverages with high tyramine content (e.g., aged cheese, cured meats, fermented foods) only if patient is also on MAOIs; not a specific requirement for amoxapine alone. Grapefruit juice may inhibit metabolism; advise caution or avoid large amounts. For patients with hypertension or seizure disorders, avoid excessive caffeine.
Avoid grapefruit and grapefruit juice as they may increase drug levels. Tyramine-rich foods (aged cheese, cured meats, fermented products) should be limited due to risk of hypertensive crisis. Maintain adequate fluid intake to prevent constipation.
First trimester: Limited data; risk of neural tube defects? Second trimester: No specific associations. Third trimester: Risk of neonatal withdrawal (irritability, feeding difficulties). Overall: FDA Category C; avoid in first trimester if possible.
First trimester: Amitriptyline (likely the active ingredient in AMITID) is associated with a small increased risk of congenital malformations, particularly cardiovascular defects, based on observational studies. Absolute risk is low. Second and third trimesters: Chronic use may lead to neonatal adaptation syndrome (irritability, respiratory distress) and anticholinergic effects (e.g., constipation, urinary retention). Late third trimester exposure may increase risk of persistent pulmonary hypertension of the newborn (PPHN).
Excreted in breast milk; M/P ratio not established. Use caution due to potential for infant sedation and anticholinergic effects; monitor for drowsiness and poor feeding.
Amitriptyline and its active metabolite nortriptyline are excreted into breast milk with a milk-to-plasma (M/P) ratio of approximately 0.5–1.5. Relative infant dose is low (estimated <2% of weight-adjusted maternal dose). No adverse effects reported in infants followed prospectively. The American Academy of Pediatrics considers amitriptyline compatible with breastfeeding. However, monitor infant for sedation, poor feeding, and growth.
No established dose adjustments; increased clearance in pregnancy may require dose increase to maintain efficacy; monitor therapeutic response and serum levels if available.
Pharmacokinetic changes in pregnancy (increased volume of distribution, hepatic metabolism, renal clearance) may reduce serum drug concentrations. Therapeutic drug monitoring (if available) can guide dose adjustments; clinical response may require dose increases by 30–50% in the second and third trimesters. Avoid abrupt withdrawal; taper if discontinuing.
Amoxapine is a dibenzoxazepine antidepressant with both tricyclic-like reuptake inhibition and dopamine receptor blocking properties. Monitor for extrapyramidal symptoms (EPS) and tardive dyskinesia, especially in elderly. Due to dopamine blockade, it may cause hyperprolactinemia. For patients with seizures, use cautiously; dose-dependent seizure risk is higher than with other TCAs. Onset of antidepressant effect may be 2-4 weeks. Use lower initial doses in elderly and hepatic impairment. Avoid in recent myocardial infarction.
Amitriptyline is a tricyclic antidepressant with strong anticholinergic effects; monitor for QT prolongation, especially in elderly or those with cardiac disease. Start low (10-25 mg at bedtime) and titrate slowly. Avoid in recent MI, narrow-angle glaucoma, and urinary retention. Use with caution in seizure disorders.
Take exactly as prescribed; do not increase or stop abruptly without consulting your doctor.,May cause drowsiness or dizziness; avoid driving or operating heavy machinery until you know how the medication affects you.,Avoid alcohol and other CNS depressants.,Report any muscle stiffness, tremor, restlessness, or unusual movements of the face or tongue.,Notify your doctor if you experience rapid or irregular heartbeat, difficulty urinating, or blurred vision.,May cause dry mouth; use sugarless candy or gum and maintain good oral hygiene.,Tell your doctor if you are pregnant, planning to become pregnant, or breastfeeding.,Do not take any other medications, including over-the-counter products, without approval from your healthcare provider.
Take this medication at bedtime as it may cause drowsiness.,Avoid alcohol and other CNS depressants.,Do not stop abruptly; taper under medical supervision to avoid withdrawal symptoms.,May cause dry mouth, constipation, blurred vision; report severe side effects like fainting or irregular heartbeat.,Full therapeutic effect may take 2-4 weeks.
"Combined use of Oxprenolol, a non-selective beta-blocker with intrinsic sympathomimetic activity, and Amoxapine, a tricyclic antidepressant, may lead to additive cardiovascular adverse effects. Amoxapine can inhibit the metabolism of beta-blockers via competition for CYP450 enzymes, increasing oxprenolol plasma concentrations. This interaction heightens the risk of bradycardia, hypotension, and may precipitate heart block or arrhythmias, particularly in patients with pre-existing cardiac disease."
"The combination of amoxapine, a tricyclic antidepressant with strong anticholinergic properties, and clidinium, a quaternary ammonium anticholinergic used for gastrointestinal spasms, results in additive anticholinergic effects. This can lead to excessive peripheral and central anticholinergic adverse effects such as dry mouth, blurred vision, constipation, urinary retention, tachycardia, cognitive impairment, and exacerbation of glaucoma or paralytic ileus. In severe cases, anticholinergic toxicity may manifest as hyperthermia, delirium, or seizures, particularly in elderly patients or those with pre-existing conditions."
"Telavancin, a lipoglycopeptide antibiotic, prolongs the QT interval by inhibiting the delayed rectifier potassium current (IKr) in cardiac myocytes. Amoxapine, a tricyclic antidepressant, also blocks cardiac sodium and potassium channels, leading to dose-dependent QTc prolongation. Concomitant use increases the risk of torsade de pointes, ventricular arrhythmias, and sudden cardiac death, particularly in patients with electrolyte imbalances, bradycardia, or preexisting QT prolongation."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMOXAPINE vs AMITID, answered by our medical review team.
AMOXAPINE is a Tricyclic Antidepressant that works by Selective inhibitor of serotonin reuptake and, to a lesser extent, norepinephrine reuptake. Also exhibits weak dopamine D2 receptor antagonism and alpha1-adrenergic blockade.. AMITID is a Tricyclic Antidepressant that works by Amitriptyline inhibits the reuptake of serotonin and norepinephrine, increasing their levels in the synaptic cleft. It also blocks histamine H1, alpha-adrenergic, and muscarinic receptors.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMOXAPINE and AMITID depend on the specific clinical indication. These are both Tricyclic Antidepressant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMOXAPINE is: 200-300 mg/day orally in divided doses, initially 50 mg three times daily; maximum 400 mg/day. The standard adult dose of AMITID is: 75–150 mg orally once daily at bedtime; maximum 200 mg daily. For depression, initial dose 25–75 mg/day, titrate up to 150 mg/day. For neuropathic pain, start 10–25 mg at bedtime, increase to 25–100 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMOXAPINE and AMITID in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMOXAPINE is classified as Category C. First trimester: Limited data; risk of neural tube defects? Second trimester: No specific associations. Third trimester: Risk of neonatal withdrawal (irritability, feeding difficul. AMITID is classified as Category C. First trimester: Amitriptyline (likely the active ingredient in AMITID) is associated with a small increased risk of congenital malformations, particularly cardiovascular defects, . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.